Document Detail

The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
MedLine Citation:
PMID:  15105061     Owner:  NLM     Status:  MEDLINE    
This study compared the lipid profile after three and six cycles of treatment with NuvaRing delivering 15 microg ethinylestradiol and 120 microg etonogestrel daily with a combined oral contraceptive (COC) containing ethinylestradiol 30 microg and levonorgestrel 150 microg. In the NuvaRing group 40 women were treated and 43 in the COC group. Compared with baseline, total cholesterol did not change in either group. NuvaRing did not affect HDL, but HDL, HDL2 and HDL3 levels decreased with the COC. In contrast, HDL2 increased with NuvaRing at cycle 3. LDL increased after cycles 3 and 6 with COC, and decreased after three cycles of NuvaRing treatment. Apolipoprotein A-1 levels increased with NuvaRing, but decreased with COC; apolipoprotein B and triglycerides increased, and lipoprotein(a) decreased in both groups. Sex hormone-binding globulin increased markedly more with NuvaRing, whereas corticosteroid-binding globulin levels increased less. These changes reflect the lower androgenicity of etonogestrel versus levonorgestrel and show that NuvaRing has a minimal effect on lipid profile.
M Tuppurainen; R Klimscheffskij; M Venhola; Th O M Dieben
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Contraception     Volume:  69     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-23     Completed Date:  2004-08-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  389-94     Citation Subset:  IM    
Laboratorio Gyne Oy, Kuopio, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravaginal
Administration, Oral
Apolipoproteins / blood,  drug effects
Cholesterol / blood
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
Contraceptive Agents, Female / administration & dosage,  pharmacology*
Contraceptive Devices, Female
Contraceptives, Oral, Combined / administration & dosage,  pharmacology*
Desogestrel / administration & dosage,  pharmacology
Ethinyl Estradiol / administration & dosage,  pharmacology
Levonorgestrel / administration & dosage,  pharmacology
Lipids / blood*
Triglycerides / blood
Reg. No./Substance:
0/Apolipoproteins; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Contraceptive Agents, Female; 0/Contraceptives, Oral, Combined; 0/Lipids; 0/Triglycerides; 54024-22-5/Desogestrel; 54048-10-1/3-keto-desogestrel; 57-63-6/Ethinyl Estradiol; 57-88-5/Cholesterol; 797-63-7/Levonorgestrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Emetine ditartrate: a possible lead for emergency contraception.
Next Document:  Lipid profile in women over 35 years old using triphasic combined oral contraceptives.